1
|
Mao Y, Yuan W, Gai J, Zhang Y, Wu S, Xu EY, Wang L, Zhang X, Guan J, Mao S. Enhanced brain distribution of Ginsenoside F1 via intranasal administration in combination with absorption enhancers. Int J Pharm 2024; 654:123930. [PMID: 38387820 DOI: 10.1016/j.ijpharm.2024.123930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Revised: 01/31/2024] [Accepted: 02/19/2024] [Indexed: 02/24/2024]
Abstract
Ginsenoside F1 (GF1) is a potential drug candidate for the treatment of Alzheimer's disease. Nevertheless, its low oral bioavailability and poor solubility limit clinical application. By utilizing either a direct or indirect approach, intranasal administration is a non-invasive drug delivery method that can deliver drugs to the brain rapidly. But large molecule drug delivered to the brain through intranasal administration may be insufficient to reach required concentration for therapeutic effect. In this study, using GF1 as a model drug, the feasibility of intranasal administration in combination with absorption enhancers to increase brain distribution of GF1 was explored. First of all, the appropriate absorption enhancers were screened by in situ nasal perfusion study. GF1-HP-β-CD inclusion complex was prepared and characterized. Thereafter, in vivo absorption of GF1 after intranasal or intravenous administration of its inclusion complex with/without absorption enhancers was investigated, and safety of the formulations was evaluated. The results showed that 2% Solutol HS 15 was a superior absorption enhancer. HP-β-CD inclusion complex improved GF1 solubility by 150 fold. Following intranasal delivery, the absolute bioavailability of inclusion complex was 46%, with drug brain targeting index (DTI) 247% and nose-to-brain direct transport percentage (DTP) 58%. Upon further addition of 2% Solutol HS 15, the absolute bioavailability was increased to 75%, with DTI 315% and DTP 66%. Both nasal cilia movement and biochemical substances (total protein and lactate dehydrogenase) leaching studies demonstrated 2% Solutol HS 15 was safe to the nasal mucosa. In conclusion, intranasal administration combining with safe absorption enhancers is an effective strategy to enhance drug distribution in the brain, showing promise for treating disorders related to the central nervous system.
Collapse
Affiliation(s)
- Ying Mao
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Weihua Yuan
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jiayi Gai
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Yixuan Zhang
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | | | - En-Yu Xu
- Department of Forensic Toxicological Analysis, School of Forensic Medicine, China Medical University, Shenyang 110122, China.
| | - Luyao Wang
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Xin Zhang
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China
| | - Jian Guan
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China
| | - Shirui Mao
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China.
| |
Collapse
|
2
|
Wang H, Yuan Y, Qin L, Yue M, Xue J, Cui Z, Zhan X, Gai J, Zhang X, Guan J, Mao S. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models. J Control Release 2024; 366:746-760. [PMID: 38237688 DOI: 10.1016/j.jconrel.2024.01.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 01/12/2024] [Accepted: 01/15/2024] [Indexed: 01/23/2024]
Abstract
Faced with the threat of lung cancer-related deaths worldwide, small interfering RNA (siRNA) can silence tumor related messenger RNA (mRNA) to tackle the issue of drug resistance with enhanced anti-tumor effects. However, how to increase lung tumor targeting and penetration with enhanced gene silencing are the issues to be addressed. Thus, the objective of this study is to explore the feasibility of designing non-viral siRNA vectors for enhanced lung tumor therapy via inhalation. Here, shell-core based polymer-lipid hybrid nanoparticles (HNPs) were prepared via microfluidics by coating PLGA on siRNA-loaded cationic liposomes (Lipoplexes). Transmission electron microscopy and energy dispersive spectroscopy study demonstrated that HNP consists of a PLGA shell and a lipid core. Atomic force microscopy study indicated that the rigidity of HNPs could be well tuned by changing thickness of the PLGA shell. The designed HNPs were muco-inert with increased stability in mucus and BALF, good safety, enhanced mucus penetration and cellular uptake. Crucially, HNP1 with the thinnest PLGA shell exhibited superior transfection efficiency (84.83%) in A549 cells, which was comparable to that of lipoplexes and Lipofectamine 2000, and its tumor permeability was 1.88 times that of lipoplexes in A549-3T3 tumor spheroids. After internalization of the HNPs, not only endosomal escape but also lysosomal exocytosis was observed. The transfection efficiency of HNP1 (39.33%) was 2.26 times that of lipoplexes in A549-3T3 tumor spheroids. Moreover, HNPs exhibited excellent stability during nebulization via soft mist inhaler. In conclusion, our study reveals the great potential of HNP1 in siRNA delivery for lung cancer therapy via inhalation.
Collapse
Affiliation(s)
- Hezhi Wang
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Ye Yuan
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Lu Qin
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Mengmeng Yue
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jingwen Xue
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Zhixiang Cui
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Xuanguang Zhan
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jiayi Gai
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Xin Zhang
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China
| | - Jian Guan
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China
| | - Shirui Mao
- School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China.
| |
Collapse
|
3
|
Wang F, Chen X, Gai J, Ma YL. [A preliminary investigation of the clinical characteristics of community acquired pneumonia with concomitant pulmonary embolism]. Zhonghua Jie He He Hu Xi Za Zhi 2021; 44:525-530. [PMID: 34102713 DOI: 10.3760/cma.j.cn112147-20210329-00208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To understanding the clinical characteristics of the patients of pneumonia concomitant with acute pulmonary embolism, and the early identification of high-risk patients. Methods: Retrospective analysis of hospitalized patients with confirmed diagnosis of community acquired pneumonia (CAP) with concomitant pulmonary embolism (PE) within a period of 5 years. Patients hospitalized with CAP alone in the same period were included in the control group in a ratio of 1∶2 according to the principle of gender and age. The demographic characteristics, clinical feature, laboratory examination, radiographic and other clinical data of these 2 groups of patients were studied. Statistical analysis was performed by Chi-square test, Kruskal-Wallis test and logistic regression. Results: Thirty-nine patients with CAP combined with PE and 78 patients with CAP alone were included. Compared to patients with CAP alone, dyspnea (21/39 vs 21/78, P=0.004), a history of heart disease (10/39 vs 8/78, P=0.031), and a history of connective tissue diseases (3/39 vs 0/78, P=0.035) were more common to seen in patients with CAP combined with PE. D-dimer [2 222(854, 3 539) ng/ml vs 295(168, 707) ng/ml, P=0.000], arterial PH value (7.5±0.5 vs 7.4±0.4, P=0.022), BNP [103.9(48.7, 236.8) pg/ml vs 98.4(44.8, 246.3) pg/ml, P=0.028] and incidence of lower extremity venous thrombosis (18/39 vs 3/41, P=0.000) were higher in patients with CAP combined with PE, while arterial partial pressure of CO2 [(35.3±6.2) mmHg vs (38.4±4.4) mmHg, P=0.009, 1 mmHg=0.133 kPa] was lower. Logistic regression analysis showed that D-dimer (P=0.000) and dyspnea (P=0.033) were associated with the risk of PE. Conclusion: When patients with CAP represent dyspnea or have a history of heart disease or connective tissue diseases concomitant PE should be considered for differential diagnosis. Determination of D-dimer, arterial PH value, arterial partial pressure of CO2, BNP and ultrasonography of lower extremities had important implications for the diagnosis of pneumonia complicated with acute pulmonary embolism.
Collapse
Affiliation(s)
- F Wang
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital,Beijing 100044, China
| | - X Chen
- Department of Respiratory, People's Hospital of Xiajin County, Dezhou 253200,China
| | - J Gai
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital,Beijing 100044, China
| | - Y L Ma
- Department of Respiratory and Critical Care Medicine, Peking University People's Hospital,Beijing 100044, China
| |
Collapse
|
4
|
Root JM, Gai J, Sady MD, Vaughan CG, Madati PJ. Identifying Risks for Persistent Postconcussive Symptoms in a Pediatric Emergency Department: An Examination of a Clinical Risk Score. Arch Clin Neuropsychol 2021; 37:30-39. [PMID: 33993203 DOI: 10.1093/arclin/acab032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Revised: 01/13/2021] [Accepted: 04/20/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE External examination of a clinical risk score to predict persistent postconcussive symptoms (PPCS) in a pediatric emergency department (ED). METHODS Prospective cohort study of 5- to 18-year-old patients diagnosed with an acute concussion. Risk factors were collected at diagnosis and participants (n = 85) were followed to determine PPCS 30 days postinjury. Univariate logistic regression analyses were completed to examine associations of risk factors with PPCS. RESULTS Headache and total clinical risk score were associated with increased odds of PPCS in the univariate analyses, OR 3.37 (95% CI 1.02, 11.10) and OR 1.25 (95% CI 1.02, 1.52), respectively. Additionally, teenage age group, history of prolonged concussions, and risk group trended toward association with PPCS, OR 4.79 (95% CI 0.93, 24.7), OR 3.41 (95% CI 0.88, 13.20), and OR 2.23 (95% CI 0.88, 5.66), respectively. CONCLUSION Our study supports the use of multiple variables of a clinical risk score to assist with ED risk stratification for pediatric patients at risk for PPCS.
Collapse
Affiliation(s)
- J M Root
- Division of Emergency Medicine, Children's National Health System, Washington, DC, USA
| | - J Gai
- Children's Research Institute, Children's National Health System, Washington, DC, USA
| | - M D Sady
- Division of Pediatric Neuropsychology, Children's National Health System, Washington, DC, USA
| | - C G Vaughan
- Division of Pediatric Neuropsychology, Children's National Health System, Washington, DC, USA
| | - P J Madati
- Division of Emergency Medicine, Children's National Health System, Washington, DC, USA
| |
Collapse
|
5
|
Wang J, Gai J. [Identification of major gene and polygene mixed inheritance model and estimation of genetic parameters of a quantitative trait from F2 progeny]. Yi Chuan Xue Bao 1997; 24:432-40. [PMID: 9494295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
It has been proved by many field experiments and QTL mapping results that among genes affecting some quantitative traits there are some major genes with larger genetic effect and some polygenes with smaller genetic effect. For such traits, the distribution of segregating population demonstrates multimodality, and this is the characteristic of the mixture of more than one distributions. Mixture distribution models have been used extensively as models in a wide variety of practical situations where data can be viewed as arising from two or more populations mixed in certain proportions. Akaike's Information Criterion(AIC) has been used to identify the existence of major genes affecting quantitative traits. Under the existence of major genes, the genetic effects of these genes and their genetic variance were estimated through segregation analysis. The genotype of major gene of F2 individuals of were determined by clustering using Bayesian criterion. With P1, P2, F1 and F2 populations, the likelihood ratio test was used to test the existence of polygenes. In the end, the inheritance of soybean flowering date is analyzed. One major gene was found in F2 population derived from Guludou x Shanghaihongmangzao.
Collapse
Affiliation(s)
- J Wang
- Soybean Research Institute, Nanjing Agricultural University
| | | |
Collapse
|
6
|
Wrather JA, Anderson TR, Arsyad DM, Gai J, Ploper LD, Porta-Puglia A, Ram HH, Yorinori JT. Soybean Disease Loss Estimates for the Top 10 Soybean Producing Countries in 1994. Plant Dis 1997; 81:107-110. [PMID: 30870925 DOI: 10.1094/pdis.1997.81.1.107] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
Soybean disease loss estimates were compiled for the 1994 harvested crop from the 10 countries with the greatest soybean production. The objective was to document the major soybean disease problems in these countries and any recent changes in the severity of individual soybean diseases. Total yield losses caused by Heterodera glycines in these 10 countries were greater than those caused by any other disease. Next in order of importance were stem canker, brown spot, and charcoal rot. The total yield loss due to disease during 1994 in these countries was 14.99 million metric tons, valued at $3.31 billion. Methods used to estimate soybean disease losses were field surveys, plant disease diagnostic clinic samples, variety trial data, information from field workers and university extension staff, research plots, grower demonstrations, and private crop consultant reports. Yield loss estimates due to a particular disease varied by country. For example, yield losses due to rust were reported from China and Indonesia, but no losses due to this disease were reported from any of the remaining eight countries. Soybean disease control research and extension efforts are needed to provide more effective preventive and therapeutic disease management strategies and systems to producers.
Collapse
Affiliation(s)
- J A Wrather
- University of Missouri-Delta Center, P. O. Box 160, Portageville 63873
| | - T R Anderson
- Harrow Research Center, Harrow, Ontario N0R 1 G0 Canada
| | - D M Arsyad
- Ministry of Agriculture, Agency for Agriculture Research and Development, BORIF, Jalan Tentara Pelajar No. 3A, Bogor 16111, Indonesia
| | - J Gai
- Soybean Research Institute, Nanjing Agricultural University, Weigang, Nanjing, Jiangsu 210014, China
| | - L D Ploper
- Estación Experimental Agroindustrial Obispo Colombres, Casilla de Correo 9, 4101 Las Talitas, Tucumán, R. Argentina
| | - A Porta-Puglia
- Istituto Sperimentale per la Patologia Vegetale, Via Bertero 22, 00156 Roma, Italy
| | - H H Ram
- G. B. Pant University of Agriculture & Technology, Pantnagar - 263145, U. P., India
| | - J T Yorinori
- CNPSoja - EMBRAPA, Caixa postal 231, 86001-970 Londrina - Paraná - Brasil
| |
Collapse
|
7
|
Arnone M, Baroni M, Gai J, Guzzi U, Desclaux M, Keane P, LeFur G, Soubrié P. Effect of SR 59026A, a new 5-HT(1A) receptor agonist, on sexual activity in male rats. Behav Pharmacol 1995; 6:276-282. [PMID: 11224336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The effect of SR 59026A, a new selective 5-HT(1A) receptor agonist, was evaluated on sexual behaviour of male rats in different experimental conditions. SR 59026A (1-10mg/kg p.o.) stimulated the copulatory behaviour of sexually experienced rats, as evidenced by a decrease in the number of pre-ejaculatory mounts and intromissions and a shortening of the ejaculation latency. SR 59026A also facilitated the sexual behaviour of naive male rats characterized by a low level of sexual performance: over the same dose range, the percentage of naive males that copulated was significantly increased and the ejaculation latency reduced. In experiments designed to evaluate the onset of sexual satiation, SR 59026A (1 and 3mg/kg) increased significantly the number of ejaculations and delayed the time of sexual satiation. Finally, in agreement with studies on other 5-HT(1A) receptor agonists, SR 59026A did not modify the occurrence of spontaneous erections in isolated male rats. Therefore, the present study shows that SR 59026A improves the sexual performance of male rats in a number of different experimental models, and the compound may prove to be of interest for the treatment of certain states of human male sexual dysfunction.
Collapse
Affiliation(s)
- M. Arnone
- Sanofi Recherche, 195 route d'Espagne, 31036 Toulouse Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|